Skip to content

pregabalin effect on Oxaliplatin-induced-neuropathy

Evaluation of pregabalin effect on treatment of Oxaliplatin-induced-neuropathy in patients with colorectal cancer with Folfox regime

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231022059806N1
Enrollment
176
Registered
2023-11-05
Start date
2023-10-29
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer. Malignant neoplasm of rectosigmoid junction

Interventions

Intervention 1: Intervention group: In addition to the main cancer treatment regimen, patients will also receive pregabalin chemotherapy at a dose of 75 mg every 12 hours for one month in the first mo

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Colorectal cancer diagnosis Age above 18 years Not using other chemotherapy regimen at the same time

Exclusion criteria

Exclusion criteria: Previous history of neuropathy Diagnosis of polymyositis Renal failure (GFR less than 50) Liver failure (liver enzymes more than 2-3 times normal) Diabetic patients.

Design outcomes

Primary

MeasureTime frame
The amount of neuropathy in these patients will be measured. Timepoint: In order to check the duration of neuropathy in these patients, this questionnaire will be completed 3 months and 6 months after the end of treatment. Method of measurement: The amount of neuropathy in these patients will be measured based on a grading scale of 0 to 10. In assessing the severity of painful neuropathy based on this criterion: 0 indicates that the patient has no pain and 10 indicates the most pain that the patient has ever experienced.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Aliakbarzadeh

Ghoum University of Medical Sciences

amirqeqe@gmail.com+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026